<DOC>
	<DOC>NCT00469027</DOC>
	<brief_summary>The primary objective is to establish the safety of autologous progenitor cell-based gene therapy of heNOS in patients with severe Pulmonary Arterial Hypertension(PAH) refractory to conventional treatment.</brief_summary>
	<brief_title>Pulmonary Hypertension: Assessment of Cell Therapy</brief_title>
	<detailed_description>This is a two centre, phase I clinical trial. A total of 18 patients will be studied using an open-label, dose escaling protocol; three patients will be entered into each of the five dosing panels. An additional three patients will be entered into the final dose panel to establish safety at the maximum tolerated dose.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<criteria>Clinical diagnosis of idiopathic Pulmonary Arterial Hypertension Familial PAH or anorexigen induced PAH Specified 6minute walk distance Intra or extra cardiac communication between the right and left sided circulations Hemodynamic instability Left ventricular ejection fraction &lt; 40% Thromboembolic event or recent hospitalization for worsening right sided heart failure in past 3 months CVP&gt;20mmHg at time of research heart catheterization Pregnancy Concurrent hepatitis or HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pulmonary Arterial Hypertension (PAH)</keyword>
</DOC>